To include your compound in the COVID-19 Resource Center, submit it here.

Sanifit's SNF472 meets in Phase II for rare vascular calcification syndrome

Laboratoris Sanifit S.L. (Palma de Mallorca, Spain) said IV SNF472 met the primary endpoint of improving wound healing from baseline to

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE